Abstract
Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease that is associated with multiple metabolic disturbances, yet the metabolic pathways underlying its progression are poorly understood. Here we studied metabolic pathways of the human liver across the full histological spectrum of NAFLD. We analyzed whole liver tissue transcriptomics and serum metabolomics data obtained from a large, prospectively enrolled cohort of 206 histologically characterized patients derived from the European NAFLD Registry and developed genome-scale metabolic models (GEMs) of human hepatocytes at different stages of NAFLD. We identified several metabolic signatures in the liver and blood of these patients, specifically highlighting the alteration of vitamins (A, E) and glycosphingolipids, and their link with complex glycosaminoglycans in advanced fibrosis. Furthermore, we derived GEMs and identified metabolic signatures of three common NAFLD-associated gene variants (PNPLA3, TM6SF2 and HSD17B13). The study demonstrates dysregulated liver metabolic pathways which may contribute to the progression of NAFLD.
Competing Interest Statement
J.M.S declares Consultancy: Boehringer Ingelheim, BMS, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Novartis, Novo Nordisk, Nordic Bioscience, Pfizer, Roche, Sanofi, Siemens Healthcare GmbH. Research Funding: Gilead Sciences, Boehringer Ingelheim. Speakers Bureau: Falk Foundation MSD Sharp & Dohme GmbH. M.A. reports consultancy/advisory with MedImmune/Astra Zeneca and E3Bio, as well as honoraria from Intercept and grant support from GSK and Takeda. E.B. reports advisory/consulting for BMS, Genfit SA, Gilead, Intercept, and Novartis. Q.M.A. reports grants, personal fees and other from Allergan/Tobira, other from E3Bio, other from Eli Lilly & Company Ltd, other from Galmed, grants, personal fees and other from Genfit SA, personal fees and other from Gilead, other from Grunthal, other from Imperial Innovations, grants and other from Intercept Pharma Europe Ltd, other from Inventiva, other from Janssen, personal fees from Kenes, other from MedImmune, other from NewGene, grants, personal fees and other from Pfizer Ltd, other from Raptor Pharma, grants and other from Novartis Pharma AG, grants from Abbvie, personal fees and other from BMS, grants from GSK, other from NGMBio, other from Madrigal, other from Servier, other from EcoR1, other from 89Bio, other from Altimmune, grants and other from AstraZeneca, other from Axcella, other from Blade, other from BNN Cardio, other from Celgene, other from Cirius, other from CymaBay, other from Genentech, other from HistoIndex, other from Indalo, other from IQVIA, other from Metacrine, other from North Sea Therapeutics, personal fees and other from Novo Nordisk, other from Poxel, other from Terns, other from Viking Therapeutics, grants from Glympse Bio, other from PathAI, outside the submitted work.
All other authors declare that they have no competing interests.
Funding Statement
This study has been supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under Grant Agreement 777377. Q.M.A. is a Newcastle NIHR Biomedical Research Centre investigator. T.H. and M.O. received funding from the Novo Nordisk Foundation (Grant no. NNF20OC0063971). M.O. was also supported by the Academy of Finland (grant no. 333981). T.V.P. laboratory was funded by the MRC MDU programme grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Collection and use of samples and clinical data for this study were approved by the relevant local and/or national Ethical Review Committee covering each participating center, with all patients providing informed consent for participation. All participant recruitment and informed consent processes at recruitment centers were conducted in compliance with nationally accepted practice in the respective territory and in accordance with the World Medical Association Declaration of Helsinki 2018. List of study centers and the relevant ethical approvals is provided below. Center: Freeman Hospital, Newcastle upon Tyne, UK & Hospitals NHS Trust, Newcastle upon Tyne, UK. Approval: North East - Tyne & Wear South Research Ethics Committee Approval 15/NE/0150. Center: Addenbrookes Hospital, Cambridge, UK. Approval: North East - Tyne & Wear South Research Ethics Committee Approval 15/NE/0150. Center: Nottingham University Hospitals NHS Trust, Nottingham, UK. Approval: North East - Tyne & Wear South Research Ethics Committee Approval 15/NE/0150. Center: Inselspital Hospital, Bern, Switzerland. Approval: Inselspital Direktion Lehre und Forschung Bestaetigung Nr. 07.09.67 Studie Nr. 2034. Center: Antwerp University Hospital, Belgium. Approval: Univeriteit Antwerpen Ethisch Comite B30020071389. Center: Pitie-Salpetriere Hospital, Paris, France. Approval: CPP Ile-de-France VI DC-2014-2317. Center: University Hospital, Linkoping, Sweden & Oskarshamn County Hospital, Sweden. Approval: Ethics committee at University Hospital in Linkoping (02-454, amendments: 2011/468-32, 2012/229-32, and 2013/72-32). Center: University Medical Center, Mainz, Germany. Approval: Landesaerztekammer Rheinland-Pfalz Ethik-Kommission 837.199.10 (7208). Center: Citta della Salute e della Scienza di Torino Hospital, Turin, Italy. Approval: Comitato Etico Interaziendale 0113185. Center: Section of Gastroenterology and Hepatology, University of Palermo, Italy. Approval: Comitato Etico Palermo 1 7.01.2017. Center: Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy. Approval: Institutional Review Board of the Fondazione Ca Granda IRCCS of Milan.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint senior authors
Expanded analyses of the data, resulting to changes in results section and additional supplemental figures. Conclusions and discussions unchanged (except for minor language edits).
Data Availability
Scripts for GSMM, contextualization and data analysis can be downloaded from (https://github.com/parthoBTK/Personalized_Liver_Models.git). The personalized GEMs (.mat files) of human-hepatocytes contextualized for different stages of NAFLD, and three major gene variants are available upon request. The RNA-Seq data are available in the NCBI GEO repository (accession GSE135251). The lipidomic / metabolomic datasets generated in this study were submitted to the Metabolomics Workbench repository (https://www.metabolomicsworkbench.org) and were assigned a project ID PR001091 (doi: 10.21228/M8P97V).
